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Abstract
Background and aims: Obesity and overweight are major public health issues. Although traditionally
associated with weight loss, there is now evidence that increasing Body Mass Index (BMI) and
overweight are emerging features of Crohn's disease (CD) and may be associated with more severe
disease course.
The aim of the study was to determine the prevalence of overweight and obesity in patients with
CD compared with matched healthy controls and to identify disease-specific and generic factors rch 1, 2016associated with current BMI in this group.
Methods: This was a prospective case–control study (n=200), comprising 100 CD outpatients and 100
age-, sex- and socioeconomically-matched healthy controls. BMI, Crohn's disease activity index
(CDAI), clinical and lifestyle factors and circulating inflammatory markers were assessed.
Results: Overall, 40% of patients with CD were overweight/obese (BMI≥25 kg/m2) compared with
52% of controls (P=0.206). On regression analysis, higher current BMI was significantly associatedwith
disease specific factors, namely lower disease activity (CDAI) and lower white cell count, suggesting
stable disease, as well as older age and lower physical activity. BMI was not significantly associated
with the need for surgery or the need for corticosteroids. We identified a novel association between
higher BMI and higher CRP, a marker linked both with obesity in the general population and with CD.
Conclusions: Overweight was common in out-patients with CD and appeared to reflect current
wellness, older age and sedentary lifestyles. The potential long-term implications of high BMI for
CRP and inflammatory load merit further study.
© 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.t of Clinical Medicine, Trinity Ce
2988.
d.ie (M. O'Sullivan).
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 1. Introduction
Obesity and overweight are major public health issues in West-
ern populations.1,2 Although Crohn's Disease (CD) is traditionally
associated with weight loss and low Body Mass Index (BMI),
there is evidence that this may be changing. Weight loss and
malnutrition are well-documented features of CD, affecting an
estimated 80% of patients during acute flare-ups and hospital
admissions3–5 and are associated with higher mortality,3 longer
hospital stays and higher health care costs.4 Paradoxically,
overweight is now emerging as a further nutritional issue af-
fecting people with CD.6,7 Sousa Guerreiro et al.6 noted that
32% of CD patients with mild or inactive CD were overweight, of
which 8%were obese. Steed et al.8 found that over half (55%) of
CD patients were overweight/obese, in a cohort that included
both active and inactive disease. In a large study of children
with newly diagnosed CD, most (66–69%) were in the normal
range for BMI and 10% were classed as overweight or at risk for
overweight.7,9 Similarly in established CD, 20% of children were
reportedly overweight or obese.9
The question remains as to the clinical relevance of over-
weight and obesity in adult CD. In particular, does a higher BMI
have a negative impact on disease course and severity, as
some studies suggest?10,11 There are limited published data on
this issue. In adults with CD, Blain et al.,10 reported that obese
patients were more prone to developing active disease. Haas
et al.11 found that surgery was required sooner for over-
weight/obese compared with underweight CD patients. In
children with CD, higher rates of surgery have been reported
in overweight/obese than in normal weight patients.9 Fur-
thermore, recovery from surgerymay be impaired by high BMI,
post-operatively obese patients with ulcerative colitis (UC)
had significantly longer hospital stays and a higher incidence
of complications.12 Taken together, the existing data suggest
that overweight/obesity may have a negative impact on
disease course in CD, but this area remains largely unexplored.
The mechanisms underlying the putative effects of over-
weight and obesity on CD are not known. While there is a
long-established link between adipose tissue and inflammation
in CD, this has predominantly focussed on intra-abdominal
(mesenteric) fat as opposed to systemic body fat characteristic
of obesity. A build up of intra-abdominal fat is a known feature
of CD,13 reportedly acting as a source of adipocytokines and
implicated in the pathogenesis of intestinal inflammation.14–16
This phenomenon of intra-abdominal fat, however, appears to
be independent of overweight and obesity and not necessarily
associated with changes in BMI.16,17 How excessive systemic
adipose tissue influences inflammatory processes in CD is less
clear. In the general population, obesity is associated with
higher C-reactive protein (CRP)18–20 and Tumour Necrosis
Factor-alpha (TNF-alpha) levels21,22 and obesity is considered
an inflammatory state.21 In the longer term, overweight in CD
may increase the risk of co-morbid diseases such as diabetes,
cardiovascular diseases and cancer, as in the general public.
Coronary heart disease, for example, may be more common in
IBD than controls23,24 but its aetiology appears to be complex
and is driven by chronic inflammation23 as well as conventional
risk factors, such as obesity.
Considering that overweight is now endemic in Western
populations and is an emerging issue in CD, we set out to
investigate the role of increasing BMI in this disease. This
study aimed to identify the characteristics that distinguishoverweight fromnormal weight CD and to determine if current
high BMI was associated with markers of more severe CD, as
has been suggested by previous studies.2. Methods
2.1. Patient selection and recruitment
Adult patients (N18 years) with a confirmed diagnosis25 of
CD (n=100) for a minimum of 3 months were prospectively
recruited from the IBD out-patient clinics of the Adelaide
& Meath Hospital, Dublin, Ireland. Age-, sex- and
socioeconomically-matched healthy controls (n=100)
were recruited from non-medical departments and busi-
nesses within the hospital's catchment area. The study was
approved by the ‘St James's Hospital and the Adelaide &
Meath Hospital, incorporating the National Children's
Hospital Dublin, Research Ethics Committee'. All partici-
pants gave written informed consent.2.2. Demographic, clinical and lifestyle data
Data on demographics, socioeconomic status26 and smoking
habits were recorded at interview for all participants. Clinical
variables, including previous need for CD related surgery and
corticosteroid usage in past year were documented. Physical
activity was estimated using the European Prospective Inves-
tigation into Cancer Physical Activity Questionnaire (EPAQ2)27
and data expressed as metabolic equivalent (MET) per week.
Hours spent watching television (including computer games,
DVDs)was further used as a simplemarker of physical inactivity
and sedentary lifestyles.282.3. Weight and Body Mass Index
Height, weight and Body Mass Index (BMI) (kg/m2) were re-
corded. Height was measured to the nearest 0.1 cm using a
portable stadiometer (Seca Ltd., UK) and body weight to the
nearest 0.1 kg using electronic scales (Seca Ltd., UK). Weight
and height measures were performed on subjects wearing
light indoor clothing and without shoes. Weight status was
classified according to BMI, where underweight was defined as
a BMI of b18.5 kg/m2, normal weight as 18.5–24.9 kg/m2,
overweight was defined as BMI of 25–29.9 kg/m2 and obese as
≥30 kg/m2.29 The general term overweight/obese was used
to describe BMI≥25 kg/m2.2.4. Adiposity
Adiposity (body fat stores) was assessed using two anthro-
pometric parameters, namely triceps skinfold thickness
(TST) and arm fat area (AFA), both performed and
interpreted in accordance with standard protocols30 and
was measured in triplicate using a skinfold calliper (Holtain
Ltd, Pembrokeshire, UK). AFA was calculated from triceps
skinfold thickness values combined with measurements of
the mid upper-arm circumference.31
Table 1 Characteristics of the study population.
CD
(n=100)
Controls
(n=100)
p
Age, years, mean (s.d.) 35.7 (10.9) 37.9 (11.0) 0.153
Gender (male:female) 40:60 40:60 1.000
Weight, kg, mean (s.d.) 71.2 (17.1) 72.6 (13.9) 0.523
Height (m), mean (s.d.) 1.68 (0.1) 1.69 (0.1) 0.853
BMI, kg/m2 , mean (s.d.) 25.08 (5.5) 25.43 (3.8) 0.596
Age at onset,36 years, %
A1 13 –
A2 71 –
A3 16 –
Disease duration, years (IQR) 6.5 (3.0–12.8) –
Disease location,36 %
L1 46 –
L2 28 –
L3 24 –
L4 2 –
Disease behaviour,36 %
B1 56 –
B2 25 –
B3 19 –
Perianal disease, %
B2+BP 6 –
Previous surgery for CD, (%) 29 –
Disease activity
CDAI, median (IQR) 91.1 (38.4–173.9) –
CRP mg/L, median (IQR) 3.7 (2.9–8.0) –
Remission by CDAIb150, (%) 67 –
Assessment of adiposity
TST mm, mean (s.d.) 20.7±7.5 20.5±7.2 0.855
AFA mm2, mean (s.d.) 2666.6±1123.3 2636.53±978.2 0.840
Smoking (%)
Current smoker 25 16 0.288
Ex-smoker 29 32
Non-smoker 46 52
TV hours per week, mean (s.d.) 21.1 (9.7) 16.7 (8.2) 0.010
Medication (%)
Current steroid use 22 –
Prednisolone 11 –
Budesonide 10 –
Other 1 –
Steroid use in the past 12 months 37 –
Current immosuppressant use 45 –
Current 5-ASA use 77 –
Current biologics use 15 –
Family history of IBD (%) 42
BMI, Body Mass Index; TST, triceps skinfold thickness; AFA, arm fat area; IBD, Inflammatory bowel disease; CDAI, Crohn's disease activity
index, IQR, inter-quartile range.
A1, age at diagnosis younger than 17 years; A2, age at diagnosis 17 to 40 years; age at diagnosis older than 40 years; B1, nonstricturing,
nonpenetrating disease; B2, stricturing disease; B3, penetrating disease; BP, perianal disease; L1, terminal ileum; L2, colon; L3,
ileocolonic; L4, upper gastrointestinal tract (by Montreal classification36).
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 2.5. Inflammatory markers
Disease activity was determined using the Crohn's disease
activity index (CDAI)32 where values less than 150 repre-
sented clinical remission. A venous blood sample was taken
from patients at study entry. CRP and white blood cell count
(WCC) were measured with normal ranges considered less
than 5 mg/L and 4–11 cells×109/L respectively. SerumTNF-alpha (pg/mL) was measured by an enzyme linked
immunosorbent assay (Biosource, Belgium) in duplicate and
in accordance with the manufacturer's protocol.
2.6. Statistical analysis
Data were analysed using SPSS (version 14). Comparisons be-
tween groups were performed using Student's t-test or analysis
e244 T. Nic Suibhne et al.of variance (ANOVA) with Scheffé correction for parametric
data. Chi-square and Kruskal–Wallis tests were used for non-
parametric data. Backward stepwise multiple linear regression
analysis was performed to assess the relationship between BMI
and disease-specific and lifestyle factors (CDAI, WCC, family
history of IBD, previous need for CD related surgery, need for
corticosteroid therapy, age at diagnosis, CRP, sedentary life-
style and smoking status) were explored in the model.D
o3. Results
3.0.1. Characteristics of the study group
The study comprised 200 participants. Patients (n=100)
and controls (n=100) werematched for age, gender and socio-
economic status. Patients were predominantly in disease re-
mission (67%), as defined by a CDAIb150 (Table 1).32 Fifteen
percent of patients had CDAI values of 150–199 and no partici-
pant had extremely severe disease (CDAI≥450). by guest on 
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 3.1. Prevalence of overweight/obesity in CD and
controls
Overall the prevalence of overweight/obesity (BMI≥25 kg/m2)
in CD was 40% compared with 52% in the control group (P=
0.206) (Fig. 1). Correspondingly, mean values for BMI and body
fat stores were similar in patients and healthy controls
(Table 1). The breakdown of weight category according to BMI
in patients and controls is illustrated in Fig. 1. A similar
proportion of patients (17%) and controls (12%) were classified
as obese (NS, P=0.353). Overweight (BMI 25–29.9 kg/m2) was
significantly less common in CD patients than in controls, at 23%
and 40% respectively (P=0.032). Underweight was documented
in only 2 CD patients and none of the controls. Patients with CD
were considerably more likely to be overweight/obese than
underweight in this clinical setting (40% overweight v. 2%).0
20
40
60
80
100
CD Controls
%
Obese
Overweight
Normal weight
Underweight 
0.032
0.353
0.331
p value 
Figure 1Weight classification according to BMI in CD patients
and healthy controls. CD, Crohn's disease; underweight, BMI
of b18.5 kg/m2; normal weight (healthy weight), BMI of 18.5–
24.9 kg/m2; overweight, BMI of 25–29.9 kg/m2, obese; BMI of
≥30 kg/m2.3.2. Profile of overweight/obese CD patients
compared with normal weight
Table 2 shows the characteristics of patients with CD
according to the BMI category. Overweight and obese patients
were significantly older than those in the healthy weight
category. Age at onset of disease was important, for only 7% of
healthy weight CD patients disease onset occurred at age 40 or
older, compared with 35% in the obese group. Other distin-
guishing features were the significantly lower CDAI in over-
weight and obese compared with healthy weight CD, and
lower WCC in obese compared with healthy weight patients.
Obese CD patients were more sedentary, with a significantly
lower physical activity as estimated by TV watching hours and
METs expended/week. There was a non-significant trend
towards a higher rate of elevated CRP in the obese compared
with healthy weight patients. Other disease related variables
(including surgery and steroid use) did not appreciably
distinguish overweight/obese CD patients from those classi-
fied as healthy weight according to BMI.3.3. Factors associated with BMI in CD: regression
analysis
Regression analysis (Table 3) confirmed that BMI was positively
associated with age and sedentary lifestyle and negatively
associated with both CDAI and WCC. Furthermore, higher BMI
was significantly associated with elevated CRP. In line with
this, CRP showed a significant but weak correlation with
adiposity as determined by TST (r=0.2, P=0.04) and AFA (r=
0.3, P=0.01) respectively. Other variables that did not signifi-
cantly contribute to the model were: previous need for CD
related surgery, need for corticosteroid therapy in previous
year, family history of IBD, age at diagnosis, disease location
and smoking status.M
arch 1, 20164. Discussion
This study reports a high prevalence (40%) of overweight
(BMI≥25 kg/m2) among adults with CD in an out-patient
setting. The prevalence was lower, but not significantly (P=
0.206), than age-, sex- and socioeconomically-matched healthy
controls (52%). While CD is traditionally associated with
underweight, paradoxically there now appears to be a shift
towards overweight in this disease, notably in mild or well
controlled CD. Sousa-Guerreiro et al.,6 identified excess body
weight as the most prevalent form of malnutrition in CD, with
32% classified as overweight/obese in a study of 78 Portuguese
adults with CD. In a more recent study by Yarur et al.,23 46% of
IBD patients compared with 72% of controls were overweight,
predominantly based on a cohort of Hispanic adults. As
illustrated in Table 4, studies that report overweight or obesity
in CD6,8,10,11,23,33 vary considerably from a methodological
standpoint, deriving from several geographic regions, em-
ploying different study designs, sample sizes and outcome
measures. Despite these differences, however, our data taken
in the context of these studies suggest that low BMI is no longer
a dominant characteristic of adult CD especially in quiescent
disease.
Table 2 Characteristics of patients with CD stratified by BMI category.
BMI 18.5–24.9 kg/m2
healthy weight
BMI 25–29.9 kg/m2
overweight
BMI≥30 kg/m2
obese
P value
n 58 23 17
Gender, M:F 22:36 12:11 5:12 NS
Age, years, mean (95% CI)
Current 32.8 (30.2, 35.3)ab 40.1 (35.8, 44.3)a 40.5 (33.7, 47.2)b 0.02a; 0.03b
At diagnosis 25.9 (23.5, 28.4) ab 30.6 (25.7, 35.3)a 30.5 (23.2, 37.8)b 0.22a; 0.30b
Age class at onset of CD,36 (%)
A1b17 9 17 18 NS
A2 17–40 85 b 57 47 b 0.02 b
A3 40+ 7 ab 26 a 35 b 0.01a,0.010 b
Years since diagnosis, mean (95% CI) 6.8 (5.2, 8.5)ab 10.0 (7.4, 12.7)a 10.0 (6.1, 13.9)b 0.13a; 0.21b
Previous surgery for CD (%) 31 26 23 0.70
No family history of IBD (%) 50ab 77a 69b 0.06a, 0.07b
Disease location,36 (%)
L1 48.3 52.2 29.4 NS
L2 25.9 30.4 35.3
L3 22.4 17.4 35.3
L4 3.4 – –
Disease behaviour,36 (%)
B1 53.4 56.6 64.7 NS
B2 27.6 21.7 17.6
B3 19.0 21.7 17.6
Perianal disease,36 (%)
B2+BP 8.6 4.3 5.9 NS
CDAI, mean (95% CI) 136.5 (101.0, 162.8)a 71.1 (36.4, 105.8)a 104.1 (48.1, 160.0) 0.029a
CDAIN150, % 38 22 35 NS
CRP, mg/L, median (IQR) 3.6 (2.9, 8.9) 2.9 (2.9, 7.4) 6.0 (2.9, 10.6) NS
Elevated CRPN5 mg/L, % 35b 39 52b 0.083b
Elevated CRPN10 mg/L, % 21.8 4.3 23.5 0.148
Use of steroids in the past 12 months, % 56.9 39 35.3 NS
No. of steroid courses in past year, mean (s.d) 1.21 (2.0) 0.96 (2.2) 0.47 (0.8) NS
TNF-alpha pg/mL, mean (95% CI) 6.4 (5.7, 6.9) 6.2 (5.3, 7.2) 5.9 (4.9, 6.9) NS
WCC, 109/L, mean (95% CI) 7.7 (6.9, 8.3)b 6.6 (5.7, 7.4)a 5.7 (4.8, 6.6)b 0.016 b, 0.2a
Smoking (%)
Current smoker 29 17 24 NS
Ex‐smoker 29 26 29
Non‐smoker 41 57 47
Physical activity
TV watching hours per week, mean (95% CI) 19.5 (17.0, 21.9)b 21.3 (17.3, 35.3) 27.3 (21.6, 33.0)b 0.015 b
Total METs/week, mean (95% CI) 138.9 (117.2, 160.6)b 140.0 (114.3, 165.7) 87.3 (48.9, 125.0)b 0.07 b
A1, age at diagnosis younger than 17 years; A2, age at diagnosis 17 to 40 years; age at diagnosis older than 40 years; B1, nonstricturing,
nonpenetrating disease; B2, stricturing disease; B3, penetrating disease; BP, perianal disease; L1, terminal ileum; L2, colon; L3, ileocolonic; L4,
upper gastrointestinal tract (Montreal classifications36); CDAI, Crohn's disease activity index; CRP, C reactive protein; TNF, tumour necrosis
factor; WCC, white cell count; METs, metabolic equivalents; CI, confidence interval; IQR, inter-quartile range. P value for χ2 tests, analysis of
variance (ANOVA) with Scheffé correction and Kruskal–Wallis and shown for comparisons between healthy weight versus overweighta and versus
obeseb respectively. NS, not-statically significant PN0.05.
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 A key unresolved question remains — does a high BMI
impact on disease severity or course in patients with CD? In this
study we identified that overweight/obesity was common in
adults with CD, but unlike previous reports we did not find
evidence of an association with more severe disease. In the
present study, there was a significant inverse association
between current BMI and disease activity (CDAI) and withWCC
which we suggest reflected ‘wellness’ and well controlled
disease in this out-patient setting. Consistent with this, BMI
was not associated with other parameters previously used asmarkers of severe disease such as number of previous CD
related surgeries and steroid use. In line with the healthy
control group, and with population trends, regression analysis
confirmed that BMI was significantly positively associatedwith
age and sedentary lifestyles in CD.
BMI and disease severity outcomes in CD are collated in
Table 4. Two of the cited studies10,11 suggest a negative
impact, while a third suggested a possible positive impact for
obesity.8 Haas et al.,11 in line with our findings, reported that
BMI was not associatedwith the need for surgery or numbers of
Table 3 Multiple linear regression analysis of factors associated with BMI in CD.
Variable Standardized coefficient β P value 95% confidence interval
Age, years 0.310 0.001 0.061, 0.244
White cell count, 109/L, −0.218 0.026 −0.899, -0.059
CDAI −0.205 0.036 −0.021, -0.001
Physical activity (hours of TV watching at weekends) 0.262 0.007 0.122, 0.727
Elevated CRP (N5 mg/L) 0.229 0.017 0.474, 4.596
R square value is 0.30. CDAI; Crohn's disease activity index.
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 surgeries. The negative impact highlighted by the authors was
that overweight/obese CD patients required surgery sooner
than underweight patients, however underweight is not
desirable in IBD either and is associated with increased
morbidity.3 In a retrospective study, Blain et al.10 reported
that obese patients had an increased need for medical therapy
and surgery thanmatched non-obese CD.We found that higher
BMI was associated with lower current disease activity (CDAI),
but was not related to corticosteroid usage, surgery or more
severe disease phenotype. In contrast, Steed et al.8 reported
what may be interpreted as a positive effect of higher BMI,
documenting lower levels of previous surgeries in obese
compared with normal weight CD patients. Lack of available
data combinedwith differences in study designs and endpoints
limits the interpretation of the role of higher BMI on CD. Our
data suggest that higher current BMI was associated with
stable disease in the short term.
An interesting finding was the positive association between
BMI and CRP. Higher CRP has been linked to obesity in the
general population18,19 and obesity may be viewed as an
inflammatory condition.21 Moreover, higher CRP is amarker of
inflammation in CD. The present study was not designed to
distinguish cause and effect, and whether elevated CRP levels
are a consequence of higher body fat stores or the core disease
cannot be fully determined. In the present study, however,
the association between higher BMI and higher CRP occurs
against a background of lower CDAI, lower WCC, older age and
more sedentary lifestyles in an out-patient setting. While our
data show an association between higher systemic body fat/
BMI and CRP in stable CD, others34 recently showed an
association between CRP levels and mesenteric fat in
refractory CD of normal weight. In this study, however, we
found no association between current BMI and disease activity
as measured by CDAI or with characteristics of more severe
disease phenotypes based on the Montreal criteria, suggesting
that current systemic fat mass does not appear to have a
negative impact on CD severity.
The high prevalence of overweight (40%), combined with
cigarette smoking (54% current or previous smokers) and low
levels of physical activity observed in this study is a concern
for the long term general health of adults with CD. This would
be expected to contribute to increased risk of known obesity
related diseases such as diabetes, cardiovascular diseases and
colon cancer. Well-controlled disease, as seen in this cohort,
however is also desirable to prevent inflammatory drivers of
co-morbid diseases such as colon cancer and cardiovascular
disease.23 While beyond the scope of this study, the increasing
rates of overweight and obesity in CD may begin to blur the
lines between inflammatory and traditional risk factors for
co-morbid diseases in CD.35A strength of this study was the prospective design and
assessment of BMI and collection of detailed clinical and
lifestyle data. In addition, the data can be viewed in the
context of age-, gender- and socioeconomically-matched
healthy controls from the same geographic region. We also
include several measures of disease activity and inflamma-
tion (CDAI, CRP, WCC and TNF-alpha). WCC, however, may
also be influenced by medications, although in the present
study WCC in patients taking immunosuppressants were not
significantly different than those not taking (mean
6.37×109/L and 7.6×109/L, P=0.976). Larger studies may
identify if different BMI categories reflect different disease
phenotypes or genotypes and additional variables such as
weight history, bioimpedance, intra-abdominal fat and
dietary intake data may give further insights into BMI in CD.
In conclusion, this study shows that people with stable CD
are influenced by the background population trends toward
overweight and obesity and sedentary lifestyles. The preva-
lence of overweight/obesity was 40% and underweight was
rare in this setting. Higher BMI was associated with lower CDAI
scores andWCC, suggesting stable disease, as well as older age
and less physical activity. Current BMI was not associated with
prior need for surgery, corticosteroid usage or more severe
disease phenotype. We identified a novel association between
higher BMI and higher CRP, amarker implicated in both obesity
and CD. Given that obesity is now endemic in the Western
world, future studies are needed to investigate the long-term
implications of high BMI and increasing adiposity on CRP and
inflammatory load in the CD population.5. Authors' contributions
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Table 4 Prevalence of overweight/obesity in adult Crohn's disease and postulated effect on disease specific outcomes.
Study Country Methods CD
n
Controls
n
Prevalence
of
overweight/
obesity
in CD
Prevalence of
overweight/obesity in
matched controls —
comparison with CD.
Higher BMI linked with
more severe CD?
(as denoted by need for steroids or
surgery and by complications)
Blain et al.10 France Retrospective chart
study
2065 None 3% a n/a Yes
Higher levels of medical and surgical
therapy
and more frequent perianal
complications in
obese CD.
Haas et al.11 USA Retrospective cohort
study
148 None 32% n/a Yes
Shorter time to first surgery for
overweight v. underweight.
Sousa Guerreiro et al.6 Portugal Case control study 78 80 32% 34% Not assessed
Not a study objective.
Steed et al.8 UK Retrospective study 295 Population
data
55% 61%
Lower rate of overweight/obesity in
IBD v controls
No
Lower levels of surgery (19%) in obese v.
normal weight CD (46%).
Yarur et al.23 USA Retrospective
longitudinal study
173 712 46% 72%
Significantly lower rate of overweight/
obesity and obesity in IBD v controls.
Not assessed
Not a study objective.
Mendall et al.33 UK Retrospective
questionnaire study
246 480 b 33% a 15% a
Significantly higher rate of obesity in
CD v controls at diagnosis in 50–70
age group.
Not assessed
Not a study objective.
Nic Suibhne et al.
(present study)
Ireland Prospective case
control study
100 100 40% 52%
No difference for overweight/obesity
combined. Significantly lower rate of
overweight in CD v controls.
No
BMI not associated with the need for
surgery
or steroids. Higher BMI associated with
lower
CDAI and WCC, but also with elevated
CRP.
Overweight/obesity signifies a BMI≥25 kg/m2. n/a, not applicable. v, versus.
a Represents obese only, BMIN30.
b Controls were aged 50–70 years.
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